Iberdomide

From WikiMD's WELLNESSPEDIA

Iberdomide

Immunomodulatory drug

Iberdomide





Chemical nomenclature
IUPAC name (3S)-3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione










Identifiers
CAS Number 1323403-33-3
PubChem 49846518


ChemSpider 32700838




Chemical data


Chemical formula C13H15N3O3





Iberdomide is an immunomodulatory drug that is being investigated for its potential use in the treatment of various autoimmune diseases and hematologic malignancies. It is a derivative of thalidomide and belongs to a class of drugs known as cereblon (CRBN) modulators.

Mechanism of Action[edit]

Iberdomide exerts its effects by binding to the cereblon protein, which is part of the E3 ubiquitin ligase complex. This binding leads to the degradation of specific target proteins, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors involved in the regulation of immune responses. By degrading these proteins, iberdomide modulates the activity of T cells and B cells, thereby exerting its immunomodulatory effects.

Clinical Development[edit]

Iberdomide is currently undergoing clinical trials for the treatment of various conditions, including multiple myeloma, systemic lupus erythematosus (SLE), and other autoimmune disorders. Early-phase clinical trials have shown promising results, with iberdomide demonstrating efficacy in reducing disease activity and improving clinical outcomes in patients with these conditions.

Side Effects[edit]

As with other immunomodulatory drugs, iberdomide may cause a range of side effects. Common side effects observed in clinical trials include fatigue, nausea, diarrhea, and cytopenias such as neutropenia and thrombocytopenia. Patients receiving iberdomide should be monitored for these potential adverse effects.

Regulatory Status[edit]

As of now, iberdomide has not yet received regulatory approval for clinical use. It remains an investigational drug, and its safety and efficacy continue to be evaluated in ongoing clinical trials.

See Also[edit]

References[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Iberdomide&oldid=5831712"